Profile data is unavailable for this security.
About the company
Percheron Therapeutics Limited, formerly Antisense Therapeutics Limited, is a biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The Company’s products include ATL1102 for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. ATL1103 is a second-generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action. By inhibiting GHr production, ATL1103 in turn reduces IGF-I levels in the blood (serum). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.
- Revenue in AUD (TTM)615.48k
- Net income in AUD-11.92m
- Incorporated2000
- Employees8.00
- LocationPercheron Therapeutics Ltd14 Wallace Avenue,, ToorakMELBOURNE 3142AustraliaAUS
- Phone+61 39827-8999
- Fax+61 39859-7701
- Websitehttps://percherontx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IDT Australia Limited | 14.12m | -5.41m | 49.43m | 156.00 | -- | 1.72 | -- | 3.50 | -0.0154 | -0.0154 | 0.0404 | 0.0667 | 0.4734 | 1.84 | 2.62 | -- | -18.15 | -9.77 | -22.59 | -11.61 | 80.11 | 84.61 | -38.33 | -23.12 | 1.12 | -50.05 | 0.1601 | -- | 100.81 | 3.09 | 36.30 | -- | -10.39 | -- |
| Tryptamine Therapeutics Ltd | -100.00bn | -100.00bn | 51.19m | -- | -- | 9.52 | -- | -- | -- | -- | -- | 0.0049 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0342 | -- | -- | -- | -- | -- | -- | -- |
| Neurotech International Ltd | 3.34m | -5.07m | 56.90m | -- | -- | 4.70 | -- | 17.06 | -0.0054 | -0.0054 | 0.0037 | 0.0117 | 0.3807 | 0.00 | 11.59 | -- | -57.86 | -134.56 | -63.92 | -163.66 | 100.00 | -- | -151.98 | -462.38 | 38.81 | -- | 0.00 | -- | 165.98 | 67.39 | 34.94 | -- | -- | -- |
| Anteotech Ltd | 514.89k | -8.88m | 67.22m | 40.00 | -- | 12.56 | -- | 130.56 | -0.0039 | -0.0039 | 0.0002 | 0.0022 | 0.0699 | -- | 2.55 | -- | -120.47 | -75.24 | -159.35 | -84.74 | -- | -- | -1,724.74 | -1,444.66 | -- | -- | 0.3055 | -- | 26.85 | 27.93 | 29.82 | -- | 68.39 | -- |
| Actinogen Medical Ltd | 291.02k | -13.04m | 73.98m | -- | -- | 3.31 | -- | 254.22 | -0.0061 | -0.0061 | 0.0001 | 0.0072 | 0.0159 | -- | 0.0433 | -- | -71.44 | -48.56 | -78.20 | -51.97 | -- | -- | -4,482.26 | -5,188.44 | -- | -163.10 | 0.0159 | -- | -20.63 | 7.31 | -21.32 | -- | -- | -- |
| Paradigm Biopharmaceuticals Ltd | 6.52m | -58.65m | 78.74m | -- | -- | 3.31 | -- | 12.08 | -0.1875 | -0.1875 | 0.0186 | 0.068 | 0.138 | -- | 1.10 | -- | -124.19 | -52.89 | -150.28 | -58.06 | 99.86 | -- | -899.60 | -543.63 | -- | -961.47 | 0.006 | -- | -23.22 | 14.97 | -12.99 | -- | -- | -- |
| Percheron Therapeutics Ltd | 615.48k | -11.92m | 88.13m | 8.00 | -- | 8.18 | -- | 143.18 | -0.0135 | -0.0135 | 0.0007 | 0.0104 | 0.045 | -- | 0.2912 | -- | -87.09 | -75.92 | -122.82 | -89.91 | -- | -- | -1,936.57 | -4,028.81 | -- | -1,956.65 | 0.0042 | -- | 59.90 | 56.21 | -4.74 | -- | -- | -- |
| Proteomics International LaboratoriesLtd | 1.41m | -6.38m | 93.01m | -- | -- | 9.87 | -- | 65.98 | -0.0507 | -0.0507 | 0.0112 | 0.0719 | 0.1346 | -- | 6.45 | -- | -61.88 | -60.46 | -67.65 | -69.49 | -- | -- | -459.82 | -290.18 | -- | -208.63 | 0.0331 | -- | -4.24 | -1.45 | -3.23 | -- | 60.39 | -- |
| Argenica Therapeutics Ltd | 192.09k | -5.48m | 98.63m | -- | -- | 6.83 | -- | 513.47 | -0.0518 | -0.0518 | 0.0019 | 0.1128 | 0.0148 | -- | 0.7326 | -- | -42.28 | -- | -50.70 | -- | -- | -- | -2,852.56 | -- | -- | -21,829.87 | 0.00 | -- | 214.90 | -- | -13.80 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Platinum Investment Management Ltd.as of 20 Aug 2024 | 96.27m | 10.68% |
